Fulcrum to Merge with Slate Medicines in $350M All-Stock Deal, $245M PIPE
FULC sits 34% above its 52-week low of $2.83 on light trading volume (0.4× avg).
Summary
Fulcrum Therapeutics will merge with Slate Medicines in an all-stock deal valuing Slate at $350M, with a $245M concurrent PIPE. Fulcrum stockholders get 5% of the combined company plus a $270M cash dividend. The combined company will advance Slate's migraine pipeline.
Key Events · M&A and Partnerships · FULC
-
Definitive Merger Agreement Signed
Fulcrum entered into a definitive merger agreement with Slate Medicines on August 16, 2026. Slate is valued at $350.0M and Fulcrum at $31.3M, with the exchange ratio subject to adjustment based on Fulcrum's net cash at closing.
-
$245M Concurrent Private Placement
Slate secured commitments for a $245M private placement led by Frazier Life Sciences, with participation from Forbion, RA Capital Management, Deep Track Capital, Foresite Capital, OrbiMed, RTW Investments, and Mingxin Capital. The financing is expected to close concurrently with the merger.
-
Ownership Split and Cash Dividend
Post-merger ownership: pre-Merger Slate stockholders 55.9%, Investors 39.1%, pre-Merger Fulcrum stockholders 5.0%. Fulcrum expects to declare a $270M cash dividend to pre-merger Fulcrum stockholders prior to closing.
-
Combined Company to Focus on Migraine Pipeline
The combined company will operate as Slate Medicines, Inc. and trade under ticker SLTE. Lead candidate SLTE-1009 is a clinical-stage subcutaneous anti-PACAP/VIP monoclonal antibody for migraine prevention, with Phase 1 data expected mid-2027.
Analysis · FULC · Life Sciences
A path forward has emerged for Fulcrum, a shell company after discontinuing its lead program and cutting 85% of staff, through a reverse merger with Slate Medicines. The deal values Slate at $350 million and includes a $245 million concurrent private placement from top-tier healthcare investors. Pre-merger Fulcrum stockholders will own just 5% of the combined company but receive a $270 million cash dividend. The combined company will focus on Slate's migraine pipeline, led by SLTE-1009, with cash runway into 2029. This is a transformative event for Fulcrum stockholders, who faced potential liquidation.
At the time of this filing, FULC was trading at $3.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $285.4M. The 52-week trading range was $2.83 to $15.74. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.